Cargando…
A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease
Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the central nervous system (CNS) leading to mental deterioration and devastation, and eventually a fatal outcome. AD affects mostly the elderly. AD is frequently accompanied by hypercholesterolemia, hypertension, atheroscle...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599320/ https://www.ncbi.nlm.nih.gov/pubmed/34121170 http://dx.doi.org/10.1007/s43440-021-00293-5 |
_version_ | 1784600922845872128 |
---|---|
author | Maciejewska, Karolina Czarnecka, Kamila Szymański, Paweł |
author_facet | Maciejewska, Karolina Czarnecka, Kamila Szymański, Paweł |
author_sort | Maciejewska, Karolina |
collection | PubMed |
description | Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the central nervous system (CNS) leading to mental deterioration and devastation, and eventually a fatal outcome. AD affects mostly the elderly. AD is frequently accompanied by hypercholesterolemia, hypertension, atherosclerosis, and diabetes mellitus, and these are significant risk factors of AD. Other conditions triggered by the progression of AD include psychosis, sleep disorders, epilepsy, and depression. One important comorbidity is Down’s syndrome, which directly contributes to the severity and rapid progression of AD. The development of new therapeutic strategies for AD includes the repurposing of drugs currently used for the treatment of comorbidities. A better understanding of the influence of comorbidities on the pathogenesis of AD, and the medications used in its treatment, might allow better control of disease progression, and more effective pharmacotherapy. GRAPHIC ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-8599320 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-85993202021-11-24 A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease Maciejewska, Karolina Czarnecka, Kamila Szymański, Paweł Pharmacol Rep Review Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the central nervous system (CNS) leading to mental deterioration and devastation, and eventually a fatal outcome. AD affects mostly the elderly. AD is frequently accompanied by hypercholesterolemia, hypertension, atherosclerosis, and diabetes mellitus, and these are significant risk factors of AD. Other conditions triggered by the progression of AD include psychosis, sleep disorders, epilepsy, and depression. One important comorbidity is Down’s syndrome, which directly contributes to the severity and rapid progression of AD. The development of new therapeutic strategies for AD includes the repurposing of drugs currently used for the treatment of comorbidities. A better understanding of the influence of comorbidities on the pathogenesis of AD, and the medications used in its treatment, might allow better control of disease progression, and more effective pharmacotherapy. GRAPHIC ABSTRACT: [Image: see text] Springer International Publishing 2021-06-13 2021 /pmc/articles/PMC8599320/ /pubmed/34121170 http://dx.doi.org/10.1007/s43440-021-00293-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Maciejewska, Karolina Czarnecka, Kamila Szymański, Paweł A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease |
title | A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease |
title_full | A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease |
title_fullStr | A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease |
title_full_unstemmed | A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease |
title_short | A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease |
title_sort | review of the mechanisms underlying selected comorbidities in alzheimer’s disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599320/ https://www.ncbi.nlm.nih.gov/pubmed/34121170 http://dx.doi.org/10.1007/s43440-021-00293-5 |
work_keys_str_mv | AT maciejewskakarolina areviewofthemechanismsunderlyingselectedcomorbiditiesinalzheimersdisease AT czarneckakamila areviewofthemechanismsunderlyingselectedcomorbiditiesinalzheimersdisease AT szymanskipaweł areviewofthemechanismsunderlyingselectedcomorbiditiesinalzheimersdisease AT maciejewskakarolina reviewofthemechanismsunderlyingselectedcomorbiditiesinalzheimersdisease AT czarneckakamila reviewofthemechanismsunderlyingselectedcomorbiditiesinalzheimersdisease AT szymanskipaweł reviewofthemechanismsunderlyingselectedcomorbiditiesinalzheimersdisease |